ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Arvinas Inc

Arvinas Inc (ARVN)

25.26
-0.04
( -0.16% )
Updated: 14:17:54

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
25.26
Bid
25.23
Ask
25.28
Volume
1,024,506
24.945 Day's Range 26.23
13.57 52 Week Range 53.08
Market Cap
Previous Close
25.30
Open
25.54
Last Trade
14
@
25.23
Last Trade Time
14:18:21
Financial Volume
$ 26,108,158
VWAP
25.4837
Average Volume (3m)
721,237
Shares Outstanding
68,431,891
Dividend Yield
-
PE Ratio
-4.67
Earnings Per Share (EPS)
-5.37
Revenue
78.5M
Net Profit
-367.3M

About Arvinas Inc

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-... Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Arvinas Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ARVN. The last closing price for Arvinas was $25.30. Over the last year, Arvinas shares have traded in a share price range of $ 13.57 to $ 53.08.

Arvinas currently has 68,431,891 shares outstanding. The market capitalization of Arvinas is $1.72 billion. Arvinas has a price to earnings ratio (PE ratio) of -4.67.

ARVN Latest News

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the...

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

Arvinas to Participate in Upcoming Investor Conferences

NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.8-3.0698388334626.0627.05524.0173350825.19562657CS
4-10.05-28.462192013635.3136.197424.0180248928.41238616CS
12-16.08-38.896952104541.3441.3424.0172123732.18557464CS
26-12.18-32.532051282137.4453.0824.0173311338.74127693CS
52-3.71-12.80635139828.9753.0813.5764753332.48924855CS
156-54.09-68.166351606879.35108.46513.5751988245.42128365CS
2603.2314.661824784422.03108.46513.5750752146.48377314CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.7891
(162.16%)
314.07M
SHCRSharecare Inc
$ 1.365
(76.27%)
42.68M
SPECSpectaire Holdings Inc
$ 0.534799
(57.29%)
59.98M
NXLNexalin Technologies Inc
$ 1.73
(57.27%)
48.76M
ICUSeaStar Medical Holding Corporation
$ 7.0001
(32.58%)
2.23M
FLFVFeutune Light Acquisition Corporation
$ 2.40
(-71.53%)
356.84k
FLFVUFeutune Light Acquisition Corporation
$ 2.94
(-64.54%)
3.42k
KAVLKaival Brands Innovations Group Inc
$ 1.425
(-50.35%)
3.63M
RWODURedwoods Acquisition Corporation
$ 4.60
(-37.92%)
1k
PBMPsyence Biomedical Ltd
$ 0.401863
(-33.02%)
2.43M
NVDANVIDIA Corporation
$ 126.4801
(-3.29%)
359.17M
AREBAmerican Rebel Holdings Inc
$ 0.7891
(162.16%)
314.07M
CRKNCrown Electrokinetics Corporation
$ 0.0405
(-19.00%)
147M
NKLANikola Corporation
$ 0.3528
(7.04%)
146.38M
ASTIAscent Solar Technologies Inc
$ 0.1119
(3.71%)
116.09M

ARVN Discussion

View Posts
Monksdream Monksdream 4 months ago
ARVN new 52=week high
👍️0
Monksdream Monksdream 4 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 4 months ago
ARVN new 52 week high
👍️0
Monksdream Monksdream 6 months ago
ARVN new 52 week high
👍️0
crudeoil24 crudeoil24 4 years ago
ARVN up 138% > "Based on data to date, we believe ARV-471 is the most promising ER-targeting therapy in the clinic, showing early signs of efficacy, a favorable tolerability profile, and better ER degradation than that previously reported for fulvestrant, the current standard of care,” said Ron Peck, Ph.D., Chief Medical Officer at Arvinas. “It is exciting to see that ARV-110 continues to be active and well tolerated in what we believe is the most heavily pretreated patient population that has ever been studied with an AR-directed therapy. Our recently initiated ARDENT Phase 2 cohort expansion is specifically designed to investigate the potential of a precision medicine approach in molecularly defined, late-line patients with few available treatment options, while also fully characterizing the safety and activity of ARV-110 in earlier line patients irrespective of molecular profile, setting ARV-110 on a potential two-pronged registrational path.”
👍️0
biocqr biocqr 5 years ago
Advantages of PROTACs vs. inhibition...

message_id=152832655
👍️0
G-lupo G-lupo 5 years ago
Idk about that, I thought it had some resistance and kept going through, I think at this next convention their going to release some positive news. I’m so holy I didn’t sell at $30 which was ceiling I thought. Do have in a $35 limit sell thought if drops. Rebuy anything under $25
👍️0
boo boo boo boo 5 years ago
Starting to see a chink in the armor!
👍️0
G-lupo G-lupo 5 years ago
Possibly wall at 30.50
👍️0
G-lupo G-lupo 5 years ago
I feel people are going to start taking profits before $35 price target and give it a dip back.
Question is what is that dip price
👍️0
boo boo boo boo 5 years ago
The offering:

8-k
👍️0
boo boo boo boo 5 years ago
Benzinga 11/14/2019:

With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.

I might post a chart in about a week, well after everything plays out!
👍️0
boo boo boo boo 5 years ago
It doesn't have to be a PR:

#8
👍️0
G-lupo G-lupo 5 years ago
Thanks, I’m in it, thought $28 would be resistant and broke through looks may break $30
👍️0
boo boo boo boo 5 years ago
https://polsonnews.com/arvinas-inc-nasdaqarvn-receives-34-33-average-pt-from-brokerages/
👍️0
G-lupo G-lupo 5 years ago
When did they Do a price target announcement? I didn’t see that.
👍️0
boo boo boo boo 5 years ago
If I were in this one (I'm not), I'd be finding the exit on the price target announcement.
👍️0
G-lupo G-lupo 5 years ago
Arvn looking good, defintely see $26-27
👍️0
G-lupo G-lupo 5 years ago
What you mean IBD?
👍️0
boo boo boo boo 5 years ago
Not me. I look for the trade setup. Learned of this one from IBD and have been following...waiting. Missed the opportunity by 1 day. Would've, Should've, Could've...
👍️0
G-lupo G-lupo 5 years ago
I agree I own a decent amount, purchased from $22 down to $15.50. In for the long haul
👍️0
boo boo boo boo 5 years ago
Missing a trade and people who post a purchase at a specific price well after that price has passed.

The bottom of the prior range (July thru September) is resistance as far as I'm concerned and you have a couple important SMA's around there. And I agree that a break of $27 could lead to a higher price. Wouldn't be as confident if a press release occurred at the same time, but then again depends on what is said.
👍️0
G-lupo G-lupo 5 years ago
What are you talking about ?

Saw the rebound at $16, going to get probably Around $25-26, if gets there look for resistance to drop back. Like this stock and with more news if breaks $27 could see $60
👍️0
boo boo boo boo 5 years ago
Screwed this one up. More and better content on biotech values board. And no, I don't think this individual bought 'yesterday' and posted about it the day after. That's crap and not credible...POSER!
👍️0
boo boo boo boo 5 years ago
Fook R's!

EOM
👍️0
boo boo boo boo 5 years ago
Price is at the 100 Lower Linear Regression channel. Do we consolidate here and eventually move north. No position...yet!
👍️0
PennyStock Alert PennyStock Alert 5 years ago
ARVN
👍️0
G-lupo G-lupo 5 years ago
This stock very volatile, no rhyme or reason why it’s been up and down.
👍️0
morokoy morokoy 5 years ago
Las Vegas man 1st in world to use new experimental cancer drug, ARV 101.

https://www.reviewjournal.com/life/health/las-vegas-man-1st-in-world-to-use-new-experimental-cancer-drug-video-1654750/
👍️0

Your Recent History

Delayed Upgrade Clock